Aberrant CpG-island methylation has non-random and tumour-type–specific patterns

J Costello, Michael C. Frühwald, Dominic J. Smiraglia, +20

Nature Genetics

Cancer ResearchEpigenetic RegulationMedicineNatural SciencesDna Methylation +9

Essential requirement for two-pore channel 1 in NAADP-mediated calcium signaling

Eugen Brailoiu, Dev Churamani, Xinjiang Cai, +8

The Journal of Cell Biology

Signal TransductionMolecular PhysiologyHyperpolarization (Biology)G Protein-coupled ReceptorCell Signaling +13

Regulatory Role of G Protein–Coupled Estrogen Receptor for Vascular Function and Obesity

Elvira Haas, Indranil Bhattacharya, Eugen Brailoiu, +17

Circulation Research

The Burden of Gastrointestinal Anastomotic Leaks: an Evaluation of Clinical and Economic Outcomes

Jeffrey Hammond, Sangtaeck Lim, Yin Wan, +2

Journal of Gastrointestinal Surgery

Patients' report on how endometriosis affects health, work, and daily life

Jessica Fourquet, Xīn Gào, Diego Zavala, +5

Fertility and Sterility

InfertilityDaily LifeEndometriosisGynecologyMenstrual Cycle +2

Prostate Cancer, Version 3.2024

Edward M. Schaeffer, Sandy Srinivas, Nabil Adra, +33

Journal of the National Comprehensive Cancer Network

Surgical OncologyCancer ManagementNccn Guidelines InsightsGynecology OncologyOncology +14

Whole-genome and Transcriptome Sequencing of Prostate Cancer Identify New Genetic Alterations Driving Disease Progression

Shancheng Ren, Gong‐Hong Wei, Dongbing Liu, +59

European Urology

BioinformaticsUrologySomatic VariantTumor HeterogeneityMedicine +7

Benefits of exenatide on obesity and non‐alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes

Ning Shao, Hong Kuang, Ming Hao, +3

Diabetes/Metabolism Research and Reviews

Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC).

Xīn Gào, Howard A. Burris, Jacqueline Vuky, +17

Journal of Clinical Oncology

Androgen ReceptorImmunologyProtac DegraderPharmacotherapyImmunotherapeutics +22

First-in-human phase I study of ARV-110, an androgen receptor (AR) PROTAC degrader in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following enzalutamide (ENZ) and/or abiraterone (ABI).

Daniel P. Petrylak, Xīn Gào, Nicholas J. Vogelzang, +5

Journal of Clinical Oncology

Androgen ReceptorUrologyProtein DegradersGenitourinary CancerFirst-in-human Phase +13